Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMG-7289 + Ruxolitinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMG-7289 | IMG7289|IMG 7289|Bomedemstat | KDM1A Inhibitor 15 | IMG-7289 irreversibly inhibits lysine-specific demethylase 1 (KDM1A, LSD1), resulting in growth inhibition of hematopoietic cells (PMID: 29453291, PMID: 31801559). | |
Ruxolitinib | Jakafi | INCB 18424|INCB018424|INCB18424 | JAK1 Inhibitor - ATP competitive 5 JAK2 Inhibitor - ATP competitive 15 | Jakafi (ruxolitinib) is an inhibitor of protein tyrosine kinases JAK1 and JAK2, thus resulting in reduced inflammation and reduced proliferation (PMID: 22474318). Jakafi (ruxolitinib) is FDA approved to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis (FDA.gov) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F TP53 R248W | acute myeloid leukemia | predicted - sensitive | IMG-7289 + Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, combination treatment with Jakafi (ruxolitinib) and IMG-7289 led to synergistic inhibition of colony formation and apoptosis induction in an acute myeloid leukemia cell line harboring JAK2 V617F and TP53 R248W in culture (PMID: 31723778). | 31723778 |
JAK2 V617F | myeloproliferative neoplasm | predicted - sensitive | IMG-7289 + Ruxolitinib | Preclinical | Actionable | In a preclinical study, combination treatment with Jakafi (ruxolitinib) and IMG-7289 demonstrated a synergistic effect, and led to decreased leukocyte and platelet counts, decreased spleen size, and decreased bone marrow stem and progenitor cell expansion in a transgenic mouse model expressing JAK2 V617F (PMID: 31723778). | 31723778 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|